Aditxt, INC 8-K filings

Aditxt, Inc. highlights its subsidiary Pearsanta's pioneering non-invasive early disease detection technology, including plans for a year-end commercial launch of prostate and endometriosis tests and a potential IPO to fund global expansion.

Aditxt, Inc. presented its strategy as a publicly owned innovation accelerator, highlighting its “unicorn farm” model, pending acquisition of Evofem, progress with Pearsanta and Adimune, and a new Bitcoin treasury strategy aimed at broadening its shareholder base and aligning enterprise value.

Aditxt, Inc. has announced a private placement of senior notes and the strategic acquisition of Evofem Biosciences, Inc.'s convertible note and warrant, alongside advancing its Adimune and Pearsanta subsidiaries towards key commercial and clinical milestones.

Aditxt, Inc. has secured short-term unsecured loans totaling $190,000 from its CEO and CIO, while also issuing a warrant for 600,000 shares to a consultant for investor marketing services.

Aditxt, Inc. announced a $70,000 loan from its Chief Innovation Officer and the appointment of Evofem Biosciences CEO Saundra Pelletier to its Board of Directors, as the company continues to navigate its pending merger with Evofem and seeks capital to advance its diverse health innovation programs.

Aditxt, Inc. and Evofem Biosciences, Inc. provided a joint update on their strategic acquisition, highlighting progress towards a September closing, global expansion, and synergistic product development in women's health.

Aditxt, Inc. announced that its CEO, Amro Albanna, provided an unsecured promissory note for $233,000 to the company, accruing interest at 7.5% per annum and due by November 22, 2025.

Aditxt, Inc. outlines its strategy to transition from a speculative microcap to a growth-oriented company by Q3 2025, emphasizing clinical trials for Adimune and assay validation for Pearsanta.

Aditxt amends its merger agreement with Evofem, extending the consummation date and providing additional investment, while Evofem reports Q1 2025 financial results.

Aditxt, Inc. has terminated its Arrangement Agreement with Appili Therapeutics, Inc., effective May 31, 2025, due to a lack of strategic alignment.

Aditxt, Inc. enters into a securities purchase agreement for $2 million to fund its bid for assets from 23andMe, while also agreeing to forbearance with preferred stockholders.

Aditxt's weekly update featured progress on ADI-100, a therapeutic candidate for autoimmune diseases, with plans for upcoming clinical trials.

Aditxt, Inc. has entered into a material definitive agreement, issuing senior notes totaling $256,250 to accredited investors to raise capital.

Aditxt's subsidiary, Pearsanta, has received IRB approval to begin clinical studies for its blood-based diagnostic test for endometriosis, aiming for a potential commercial launch in the second half of 2025.

Aditxt, Inc. reports that stockholders did not approve proposals related to the issuance of common stock underlying preferred stock and warrants at the reconvened special meeting held on April 17, 2025.

Aditxt, Inc. has entered into a Call Option Agreement, granting them the right to purchase Evofem Biosciences securities for $13 million.

Aditxt, Inc. CEO Amro Albanna highlighted the company's regained Nasdaq compliance, progress in operating subsidiaries, and ongoing strategic transactions in a recent weekly update.

Aditxt, Inc. invests $1.5 million in Evofem Biosciences through a securities purchase agreement involving a convertible note and warrant, while temporarily waiving termination rights under the existing merger agreement.

Aditxt, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, avoiding delisting.

Aditxt provides a corporate update on its potential acquisition of Appili Therapeutics, a biotech company focused on addressing infectious diseases and medical countermeasures.

Aditxt's subsidiary, Pearsanta, acquires the Adductomics platform to enhance early cancer detection and prevention capabilities.

Pearsanta, a subsidiary of Aditxt, has acquired patents related to adductomics technology to advance its platform for early cancer risk monitoring.

Aditxt, Inc. files an amendment to its previous report to include the financial statements of Appili Therapeutics as the acquisition faces continued delays and waivers.

Aditxt, Inc. files an amendment to its merger agreement with Evofem Biosciences, Inc., including audited financial statements for Evofem and pro forma consolidated financial statements reflecting the acquisitions of Evofem and Appili Therapeutics Inc.

Aditxt and Evofem Biosciences have further amended their merger agreement, extending the end date to September 30, 2025, and outlining an additional $1.5 million investment by Aditxt.

Aditxt and Evofem Biosciences CEOs provide a corporate update, emphasizing their continued partnership despite financial challenges and strategic acquisition initiatives.

Aditxt, Inc. has adjourned its special stockholder meeting for a second time, now to April 17, 2025, to allow more time for stockholders to vote on proposals related to the issuance of common stock underlying preferred stock and warrants.

Aditxt, Inc. announces a 1-for-250 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement after receiving a delisting notification.

Aditxt settles a dispute with Aldevron by agreeing to pay $1 million and issue a promissory note, while its subsidiary Adimune progresses with ADI-100, an investigational product candidate, aiming for clinical trials in autoimmune diseases.

Aditxt, Inc. held a special meeting where stockholders approved a reverse stock split and authorized the adjournment of the meeting to vote on proposals related to the issuance of common stock.